Avaí Bio, Inc. (AVAI)
| Market Cap | 17.55M -61.4% |
| Revenue (ttm) | n/a |
| Net Income | -1.81M |
| EPS | -0.01 |
| Shares Out | 153.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,092 |
| Open | 0.1260 |
| Previous Close | 0.1140 |
| Day's Range | 0.1140 - 0.1260 |
| 52-Week Range | 0.1012 - 0.8000 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Avaí Bio
Avaí Bio, Inc. acquires, creates, and develops artificial intelligence (AI) technologies. It also offers information technology (IT) consulting services. The company provides full-stack software development, database management, data integration, project management and cloud services resources. It also offers Avant! AI, a platform that has shown impressive results related to the technology’s usage, access, and performance; and InstantFAME. The company was formerly known as Avant Technologies Inc. and changed its name to Avaí Bio, Inc. in Februa... [Read more]
Financial Performance
Financial StatementsNews
Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program
LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committe...
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-relat...
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference
Avaí Bio and Austrianova presented an encapsulated-cell approach to sustained α-Klotho delivery via Klothonova at the 2026 Klotho Conference in Miami.
Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy
Avaí Bio and Austrianova complete viral and adventitious agent testing of the Master Cell Bank and establish a Working Cell Bank for α-Klotho therapy.
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova ha...
Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy
LAS VEGAS, July 21, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
LAS VEGAS, May 20, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-relat...
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
LAS VEGAS, April 7, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...
Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards
LAS VEGAS, March 3, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-rela...
Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and...
Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
LAS VEGAS, Jan. 26, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes an...
Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment
LAS VEGAS , Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes a...
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
LAS VEGAS , Dec. 9, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes an...
THE CRITICAL LIST: 5 Stocks Anchoring the New Economy
Issued on behalf of Quantum Security Encryption Corp. VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- USANewsGroup .com Market Intelligence Brief – The market is in triage. Speculative ...
Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies
LAS VEGAS--(BUSINESS WIRE)--Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related ...
Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment
LAS VEGAS--(BUSINESS WIRE)--Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and SGAustria Pte. Ltd. (SGAustria), a Singapore-based biotechnology company, ...
Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho
LAS VEGAS , Oct. 21, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company") and global biotechnology firm, Austrianova, today announced the official launch of their join...
Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies
LAS VEGAS , Sept. 25, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), today announced a pivotal evolution in its business direction, emphasizing strategic partne...
Avant Technologies, Inc. Issues Retraction of September 24, 2025 Press Release
LAS VEGAS , Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ('Avant' or the 'Company') today announced the retraction of its press release issued on September 24, 2025, regarding...
Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
LAS VEGAS , Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte.
Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies
LAS VEGAS , Sept. 18, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, and Austrianova (SGAustria Pte.
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
LAS VEGAS , Aug. 12, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging technology company developing healthcare solutions, and its Joint Venture partne...
Avant Technologies and Ainnova Tech Advance Clinical Trial Protocol Following FDA Feedback
LAS VEGAS , July 29, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging technology company developing healthcare solutions, and its Joint Venture partne...
Avant Technologies' Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
LAS VEGAS , July 22, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelli...
Avant Technologies and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA
LAS VEGAS , July 15, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company f...